Case Report
Aftermath of Apixaban: Atypical Anticoagulation Aftereffect
Table 2
Additional laboratory testing ordered.
| Lab test | Value | Reference range |
| Hepatitis C ab | Negative | Negative | Rheumatoid factor | <3.5 IU/mL | 0–39 IU/mL | CCP antibodies IgG/IgA | 5 units | 0–19 units | Antinuclear antibodies | Negative | <1 : 80 | Cytoplasmic ANCA | <1 : 20 titer | <1 : 20 | Perinuclear ANCA | <1 : 20 titer | <1 : 20 | Myeloperoxidase Ab | <9 U/mL | 0.0–9 U/mL | Proteinase-3 Ab | <3.5 U/mL | 0.0–3.5 U/mL | Atypical pANCA | <1 : 20 titer | <1 : 20 | Complement C3 | 231.8 mg/dL | 90–180 mg/dL | Complement C4 | 44.9 mg/dL | 9–36 mg/dL | Cardiolipin IgM ab | <9 U/mL | 0–12 U/mL | Cardiolipin IgG ab | <9 U/mL | 0–14 U/mL | Cardiolipin IgA ab | <9 U/mL | 0–11 U/mL | Cryoglobulin | Not detected | None | Beta-2 glycoprotein I IgG ab | <9 units | 0–20 units | Beta-2 glycoprotein I Ig M ab | 15 units | 0–25 units | Beta-2 glycoprotein I Ig A ab | 15 units | 0–32 units |
|
|